Dustin Yoon
Vascular Surgery · Germantown, MDNPI 1073839833
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,791 of the $36,217 with a category attached, or 74.0%. E.r. Squibb & Sons, L.L.C. accounts for 79.5% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2022 at $16,261 and has fallen 94.5% since, to $895 in 2025. Among vascular surgery clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $181.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$29K
- Lemaitre Vascular, Inc.$2K
- Medtronic$1K
- Silk Road Medical, Inc.$936
- W. L. Gore & Associates, Inc.$891
- Boston Scientific$658
- plus $2K from 31 others
What the payments were for
- Consulting fees$2501%
- Speaking & faculty fees$26,79174%
- Travel & lodging$3,83411%
- Food & beverage$5,34215%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 47 | $28,804 |
| Lemaitre Vascular, Inc. | 1 | $1,510 |
| Medtronic(2 entities) | 21 | $1,393 |
| Silk Road Medical, Inc. | 11 | $936 |
| W. L. Gore & Associates, Inc. | 14 | $891 |
| Boston Scientific | 19 | $658 |
| Tactile Systems Technology Inc | 16 | $607 |
| Johnson & Johnson(2 entities) | 18 | $319 |
| Smith+Nephew | 10 | $164 |
| Reflow Medical Inc | 1 | $97 |
| Cashflow Solutions, LLC | 4 | $57 |
| Bard Peripheral Vascular, Inc. | 2 | $54 |
| Surmodics, Inc. | 3 | $54 |
| Cook Medical LLC | 3 | $50 |
| Artivion, Inc. | 2 | $43 |
| Cardiovascular Systems Inc. | 4 | $40 |
| Angiodynamics, Inc. | 2 | $39 |
| Abbott | 2 | $37 |
| Integra Lifesciences Corporation | 1 | $34 |
| BD | 1 | $34 |
| Okami Medical, Inc. | 1 | $34 |
| AstraZeneca | 1 | $33 |
| Globus Medical | 1 | $32 |
| Nevro Corp. | 1 | $31 |
| Terumo Medical Corporation | 1 | $30 |
| Kerecis Limited | 1 | $26 |
| Osiris Therapeutics Inc. | 1 | $25 |
| Livanova USA, Inc. | 1 | $25 |
| EKOS Corporation | 1 | $24 |
| Biocompatibles, Inc. | 1 | $22 |
| Axogen | 1 | $20 |
| Acacia Pharma Inc | 1 | $18 |
| Pfizer | 1 | $18 |
| Organogenesis Inc. | 1 | $16 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $15 |
| Aroa Biosurgery Incorporated | 1 | $14 |
| Normatec Industries, LP | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$27,903
- VALVULOTOM$1,510
- ELLIPSYS VASCULAR ACCESS SYSTEM$915
- ENROUTE Transcarotid Neuroprotection System$718
- ENROUTE Transcarotid Stent System$718
- ENHANCE Transcarotid Peripheral Access Kit$718
- ENROUTE 0.014 Guidewire$718
- Flexitouch Plus$245
- Nimbl$245
- GORE VIABAHN Endoprosthesis with Heparin$169
- EXCLUDER AAA Endoprosthesis$152
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$140
- GORE EXCLUDER AAA Endoprosthesis$123
How this compares
$36,217 in reported general payments places this provider in the 90th percentile of 104 vascular surgery providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 101 | $125,398 |
| EliquisApixaban | 57 | $70,446 |
| ClopidogrelClopidogrel Bisulfate | 405 | $7,190 |
| Cilostazol | 39 | $789 |
| Prednisone | 19 | $43 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $319 | $125,398101 claims |
| PfizerEliquis | $18 | $70,44657 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 104 vascular surgery providers in Maryland.
Other vascular surgery in Germantown
- Jeffrey WangGermantown$53K
- Shan E Ali HaiderGermantown$3K
- Richard SilvaGermantown$2K
- Paul McNeillFrederick$302K
- John MartinAnnapolis$172K
- Caitlin HicksBaltimore$88K
- Shahab ToursavadkohiBaltimore$76K
- Michael OsgoodBel Air$57K
- Frank CriadoBaltimore$52K
- Micah GirottiBel Air$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.